Positions

Selected Publications

Academic Article

Year Title Altmetric
2023 Sustained Reduction in Pulmonary Artery Pressures and Hospitalizations During 2 Years of Ambulatory MonitoringJournal of Cardiac Failure.  29:56-66. 2023
2022 Aggressive Afterload Lowering to Improve the Right Ventricle A New Target for Medical Therapy in Pulmonary Arterial Hypertension?American Journal of Respiratory and Critical Care Medicine.  205:751-760. 2022
2021 Remote hemodynamic-guided therapy of patients with recurrent heart failure following cardiac resynchronization therapyJournal of the American Heart Association.  10:1-19. 2021
2020 Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval StudyCirculation: Heart Failure.  13:E006863. 2020
2018 Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?European Journal of Heart Failure.  20:317-322. 2018
2017 Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation ProcedureChest.  152:1128-1134. 2017
2017 Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection FractionJournal of the American College of Cardiology.  70:1875-1886. 2017
2017 Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS)European Journal of Heart Failure.  19:739-747. 2017
2017 Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trialsEuropean Journal of Heart Failure.  19:426-433. 2017
2017 Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients with Chronic Heart FailureCirculation: Heart Failure.  10. 2017
2016 Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITASJournal of Cardiac Failure.  22:815-822. 2016
2016 Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH TrialChest.  150:27-34. 2016
2016 Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day ReadmissionsCirculation: Heart Failure.  9. 2016
2016 Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure MonitoringJACC: Heart Failure.  4:333-344. 2016
2016 Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial 2016
2015 Acute heart failure in the elderly: Differences in clinical characteristics, outcomes, and prognostic factors in the Veritas studyJournal of Cardiac Failure.  21:179-188. 2015
2015 Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring deviceJournal of Cardiac Failure.  21:240-249. 2015
2015 Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitorJournal of Heart and Lung Transplantation.  34:329-337. 2015
2015 The replyAmerican Journal of Medicine.  128:e19. 2015
2014 Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database studyJournal of Heart and Lung Transplantation.  33:1304-1311. 2014
2014 Worsening heart failure, a critical event during hospital admission for acute heart failure: Results from the VERITAS studyEuropean Journal of Heart Failure.  16:1362-1371. 2014
2014 Conversion from sildenafil to tadalafil: Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) studyJournal of Cardiovascular Pharmacology and Therapeutics.  19:550-557. 2014
2014 Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fractionCirculation: Heart Failure.  7:935-944. 2014
2014 Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failureAmerican Journal of Medicine.  127:132-139. 2014
2014 Digoxin use and lower 30-day all-cause readmission for medicare beneficiaries hospitalized for heart failureAmerican Journal of Medicine.  127:61-70. 2014
2014 Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertensionJournal of Cardiac Failure.  20:485-491. 2014
2014 Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fractionJACC: Heart Failure.  2:123-130. 2014
2013 The relationships among satisfaction with social support, quality of life, and survival 5 to 10 years after heart transplantationJournal of Cardiovascular Nursing.  28:407-416. 2013
2013 Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failureAmerican Journal of Medicine.  126:701-708. 2013
2013 Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fractionCirculation: Heart Failure.  6:508-516. 2013
2013 Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES studyCirculation.  127:1128-1138. 2013
2013 Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertensionHealth and Quality of Life Outcomes.  11. 2013
2013 Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial HypertensionCardiovascular Therapeutics.  31:38-44. 2013
2013 Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective studyPharmacological Research.  78:41-48. 2013
2012 Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertensionAmerican Journal of Cardiology.  110:1546-1550. 2012
2012 Erratum: Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial (The Lancet (2011) 377 (658-666)) 2012
2011 Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patientsJournal of Cardiac Failure.  17:1012-1017. 2011
2011 Continuous Hemodynamic Monitoring in Patients With Mild to Moderate Heart Failure: Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) TrialCongestive Heart Failure.  17:248-254. 2011
2011 Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureJournal of Cardiac Failure.  17:710-717. 2011
2011 Hemodynamic factors associated with acute decompensated heart failure: Part 2 - Use in automated detectionJournal of Cardiac Failure.  17:366-373. 2011
2011 Implantable Hemodynamic MonitorsCardiology Clinics.  29:289-299. 2011
2011 Hemodynamic factors associated with acute decompensated heart failure: Part 1 - Insights into pathophysiologyJournal of Cardiac Failure.  17:282-291. 2011
2011 Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failureAmerican Heart Journal.  161:558-566. 2011
2011 A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAmerican Heart Journal.  161. 2011
2011 CHAMPION trial rationale and design: The long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring systemJournal of Cardiac Failure.  17:3-10. 2011
2011 Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial 2011
2010 Outcomes of the RESTOR-MV trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve)Journal of the American College of Cardiology.  56:1984-1993. 2010
2010 Chronic ambulatory intracardiac pressures and future heart failure eventsCirculation: Heart Failure.  3:580-587. 2010
2010 Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting systemCardiovascular Pathology.  19:117-120. 2010
2009 Invasive monitoring in patients with heart failureCurrent Cardiology Reports.  11:159-166. 2009
2009 Reduction in mitral regurgitation during therapy guided by measured filling pressures in the ESCAPE trialCirculation: Heart Failure.  2:181-188. 2009
2009 Safety and Efficacy of Ibutilide in Heart Transplant RecipientsJournal of Heart and Lung Transplantation.  28:505-507. 2009
2009 Implantable Hemodynamic MonitorsHeart Failure Clinics.  5:261-270. 2009
2008 Application of Implantable Hemodynamic Monitoring in the Management of Patients With Diastolic Heart Failure: A Subgroup Analysis of the COMPASS-HF TrialJournal of Cardiac Failure.  14:816-823. 2008
2008 Effect of treatment with continuous positive airway pressure or oxygen on sleep-disordered breathing in patients with heart failure: Results of the sleep events, Arrhythmias, and respiratory analysis in chronic heart failure (SEARCH) studyCongestive Heart Failure.  14:197-201. 2008
2008 Transition from chronic compensated to acute d compensated heart failure: Pathophysiological insights obtained from continuous monitoring of intracardiac pressuresCirculation.  118:1433-1441. 2008
2008 Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: Results of the multicenter trial of the orqis medical cancion system for the enhanced treatment of heart failure unresponsive to medical therapy (MOMENTUM)Circulation.  118:1241-1249. 2008
2008 Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial HypertensionJournal of Heart and Lung Transplantation.  27:780-788. 2008
2008 Re-stenosis After Drug-eluting Stents in Cardiac Allograft VasculopathyJournal of Heart and Lung Transplantation.  27:610-615. 2008
2008 Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. The COMPASS-HF StudyJournal of the American College of Cardiology.  51:1073-1079. 2008
2008 Task Force 8: Training in Heart Failure. Endorsed by the Heart Failure Society of AmericaJournal of the American College of Cardiology.  51:383-389. 2008
2008 A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristicsAmerican Heart Journal.  156. 2008
2008 Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial 2008
2008 Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertensionChest.  134:139-145. 2008
2007 Comparison of a Radiofrequency-Based Wireless Pressure Sensor to Swan-Ganz Catheter and Echocardiography for Ambulatory Assessment of Pulmonary Artery Pressure in Heart FailureJournal of the American College of Cardiology.  50:2375-2382. 2007
2007 Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trialsJournal of the American Medical Association.  298:2009-2019. 2007
2007 Rationale, Design, and Methods for a Pivotal Randomized Clinical Trial of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure: The MOMENTUM TrialJournal of Cardiac Failure.  13:715-721. 2007
2007 Reducing events in patients with chronic heart failure (REDUCEhf) study design: Continuous hemodynamic monitoring with an implantable defibrillator 2007
2007 Post-Heart Transplant Diastolic Dysfunction Is a Risk Factor for MortalityJournal of the American College of Cardiology.  50:1064-1069. 2007
2007 The safety of bivalirudin during elective percutaneous coronary interventions in heart transplant patientsCardiology Journal.  14:458-462. 2007
2007 Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: A multicenter clinical outcomes trial using nesiritide for TMACAmerican Heart Journal.  153:932-940. 2007
2007 Alterations in the Fibrinolytic Cascade Post-transplant: Evidence of a Bimodal Expression PatternJournal of Heart and Lung Transplantation.  26:494-497. 2007
2007 A Wireless Pressure Sensor for Monitoring Pulmonary Artery Pressure in Advanced Heart Failure: Initial ExperienceJournal of Heart and Lung Transplantation.  26:85-88. 2007
2007 A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and designCanadian Journal of Cardiology.  23:369-376. 2007
2007 Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertensionChest.  132:37-43. 2007
2006 Tissue Doppler assessment of longitudinal right and left ventricular strain and strain rate in pulmonary artery hypertension 2006
2006 Temporal trends and drug exposures in pulmonary hypertension: An American experienceAmerican Heart Journal.  152:521-526. 2006
2006 Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure PatientsJournal of the American College of Cardiology.  47:2462-2469. 2006
2006 Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart FailureJournal of the American College of Cardiology.  47:2245-2252. 2006
2006 Acute take-off of the right coronary artery with long intra-aortic wall course presenting as chronic coronary ostium occlusion in a patient with end-stage heart failureJournal of Heart and Lung Transplantation.  25:740-742. 2006
2006 Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methodsEuropean Heart Journal.  27:1431-1439. 2006
2006 Implantable hemodynamic monitoring devices in heart failureCurrent Cardiology Reports.  8:187-190. 2006
2006 Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trialAmerican Journal of Transplantation.  6:993-997. 2006
2006 Rejection with hemodynamic compromise: Objective evidence for efficacy of photopheresisJournal of Heart and Lung Transplantation.  25:283-288. 2006
2006 Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart diseaseChest.  129:1009-1015. 2006
2006 Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006Journal of Heart and Lung Transplantation.  25:1043-1056. 2006
2006 Validation and clinical utility of a simple in-home testing tool for sleep-disordered breathing and arrhythmias in heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Congestive Heart Failure (SEARCH) study.Congestive Heart Failure.  12. 2006
2005 Ultrafiltration: A new approach toward mechanical diuresis in heart failureJournal of the American College of Cardiology.  46:2052-2053. 2005
2005 Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failureJournal of Heart and Lung Transplantation.  24:2196-2201. 2005
2005 Multi-organ transplantation: Is there a protective effect against acute and chronic rejection?Journal of Heart and Lung Transplantation.  24:1828-1833. 2005
2005 Post-operative obesity and cachexia are risk factors for morbidity and mortality after heart transplant: Multi-institutional study of post-operative weight changeJournal of Heart and Lung Transplantation.  24:1424-1430. 2005
2005 Trans-telephonic monitoring of continuous haemodynamic measurements in heart failure patientsJournal of Telemedicine and Telecare.  11:240-244. 2005
2005 Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)American Heart Journal.  150:46-53. 2005
2005 Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipientsJournal of Heart and Lung Transplantation.  24:517-525. 2005
2005 Thoracic organ transplantation in the United States, 1994-2003.American Journal of Transplantation.  5:934-949. 2005
2005 The case for selective re-issuance of medical certificates to allow pilots who have received a heart transplant to resume flyingJournal of Heart and Lung Transplantation.  24:259-269. 2005
2005 Thoracic organ transplantation in the United States, 1994-2003American Journal of Transplantation.  5:934-949. 2005
2005 To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?Journal of Heart and Lung Transplantation.  24:392-400. 2005
2004 The impact of arrhythmias in acute heart failureJournal of Cardiac Failure.  10:279-284. 2004
2004 Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experienceJournal of the American College of Cardiology.  43:1973-1981. 2004
2004 Neurological events during long-term mechanical circulatory support for heart failure: The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experienceCirculation.  109:2423-2427. 2004
2004 Long-Term Follow-Up of Brachytherapy for Treatment of Allograft In-Stent RestenosisCatheterization and Cardiovascular Interventions.  61:217-221. 2004
2003 Retransplantation in 7,290 primary transplant patients: A 10-year multi-institutional studyJournal of Heart and Lung Transplantation.  22:862-868. 2003
2003 Infection in ventricular assist devices: prevention and treatment.Annals of Thoracic Surgery.  75:S48-S57. 2003
2003 Evolving trends in risk profiles and causes of death after heart transplantation: A ten-year multi-institutional studyJournal of Thoracic and Cardiovascular Surgery.  125:881-890. 2003
2003 Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantationAmerican Journal of Transplantation.  3:484-491. 2003
2003 Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertensionJournal of Cardiovascular Pharmacology.  41:293-299. 2003
2002 Treatment of end-stage heart disease with outpatient ventricular assist devicesAnnals of Thoracic Surgery.  73:1489-1494. 2002
2002 Cardiac transplant patients response to the 31P MRS stress testJournal of Heart and Lung Transplantation.  21:522-529. 2002
2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trialJournal of the American Medical Association.  287:1541-1547. 2002
2002 BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapyCirculation.  105:1348-1353. 2002
2002 Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trialAmerican Journal of Respiratory and Critical Care Medicine.  165:800-804. 2002
2002 Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failureEvidence-based Cardiovascular Medicine.  6:154-155. 2002
2001 Cardiac transplant outcome of patients supported on left ventricular assist device vs intravenous inotropic therapyJournal of Heart and Lung Transplantation.  20:449-456. 2001
2001 A multi-institutional study of cardiac retransplantation: incidence, risk factors for mortality, and outcome.Journal of Heart and Lung Transplantation.  20:181. 2001
2001 The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience.Journal of Heart and Lung Transplantation.  20:167-168. 2001
2001 Who is most likely to enjoy long term survival after cardiac transplantation? Risk stratification in a 10 year multi-institutional experience.Journal of Heart and Lung Transplantation.  20:168-169. 2001
2001 Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland.Journal of the American College of Cardiology.  37:340-370. 2001
2001 Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.Congestive Heart Failure.  7:297-308. 2001
2000 Self-report versus performance-based activities of daily living capacity among heart transplant candidates and their caregiversJournal of Clinical Psychology in Medical Settings.  7:121-132. 2000
2000 Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failureNew England Journal of Medicine.  343:246-253. 2000
2000 Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trialACP journal club.  132:425-434. 2000
2000 31P-magnetic resonance spectroscopy studies of cardiac transplant patients at restCritical Reviews in Computed Tomography.  2:51-56. 2000
2000 Activities of daily living among heart transplant candidates: Neuropsychological and cardiac function predictorsJournal of Heart and Lung Transplantation.  19:995-1006. 2000
2000 Biventricular pacing for congestive heart failure: Questions of who, what, where, why, how, and how muchAmerican Heart Journal.  140:821-823. 2000
2000 Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devicesASAIO Journal.  46:587-589. 2000
2000 Echocardiographic diagnosis of a stenotic double orifice parachute mitral valve with a single papillary muscle 2000
2000 Psychological defensiveness among heart transplant candidatesJournal of Clinical Psychology in Medical Settings.  7:167-174. 2000
2000 Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: The multicenter InSync randomized clinical evaluation (MIRACLE)Journal of Cardiac Failure.  6:369-380. 2000
2000 Rationale and design of the OPTIME CHF trial: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart FailureAmerican Heart Journal.  139:15-22. 2000
2000 Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.American Heart Journal.  139:15-22. 2000
1999 Nonpharmacologic Validation of the Intrinsic Heart Rate in Cardiac Transplant Recipients 1999
1999 Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of preoperative weight-height indicesJournal of Heart and Lung Transplantation.  18:750-763. 1999
1999 Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertensionCirculation.  99:3266-3271. 1999
1999 Consensus recommendations for the management of chronic heart failure: IntroductionAmerican Journal of Cardiology.  83. 1999
1999 Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: Results of the vesnarinone trial withdrawal substudyJournal of Cardiac Failure.  5:195-200. 1999
1998 A dose-dependent increase in mortality with vesnarinone among patients with severe heart failureNew England Journal of Medicine.  339:1810-1816. 1998
1998 Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery diseaseCirculation.  98:2248-2254. 1998
1998 Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factorsJournal of Heart and Lung Transplantation.  17:744-753. 1998
1998 Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database.Journal of Heart and Lung Transplantation.  17:744-753. 1998
1998 Efficacy of coronary stenting in the management of cardiac allograft vasculopathyAmerican Journal of Cardiology.  82:239-241. 1998
1998 Evaluation of hibernating myocardium in patients with ischemic heart diseaseAmerican Journal of Medicine.  104:69-77. 1998
1998 Intrapulmonary shunting in primary pulmonary hypertension: An observation in two patients treated with epoprostenol sodiumChest.  114:334-336. 1998
1998 Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: Initial US multicenter experiencePacing and Clinical Electrophysiology.  21:2338-2344. 1998
1998 Risk of death or incapacitation after heart transplantation, with particular reference to pilotsJournal of Heart and Lung Transplantation.  17:497-504. 1998
1997 Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-α, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipientsJournal of Heart and Lung Transplantation.  16:1046-1053. 1997
1997 Simultaneous use of an implanted defibrillator and ventricular assist deviceAnnals of Thoracic Surgery.  64:1156-1158. 1997
1997 Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrateJournal of Heart and Lung Transplantation.  16:813-821. 1997
1997 The incremental risk of female sex in heart transplantation: A multiinstitutional study of peripartum cardiomyopathy and pregnancyJournal of Heart and Lung Transplantation.  16:801-812. 1997
1997 Ventricular assist devices as a bridge to cardiac transplantation: A prelude to destination therapyAnnals of Surgery.  225:695-706. 1997
1997 Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database.Journal of Heart and Lung Transplantation.  16:813-821. 1997
1997 The incremental risk of female sex in heart transplantation: a multiinstitutional study of peripartum cardiomyopathy and pregnancy. Cardiac Transplant Research Database Group.Journal of Heart and Lung Transplantation.  16:801-812. 1997
1997 Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.Circulation.  95:1479-1486. 1997
1997 Competing outcomes after heart transplantation: A comparison of eras and outcomesJournal of Heart and Lung Transplantation.  16:190-198. 1997
1997 Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertensionCirculation.  95:1479-1486. 1997
1997 Heart Transplant Candidates: A Neuropsychological Descriptive DatabaseJournal of Clinical Psychology in Medical Settings.  4:343-355. 1997
1997 Predicting outcome after cardiac transplantations: Lessons from the Cardiac Transplant Research DatabaseCurrent Opinion in Cardiology.  12:136-145. 1997
1997 Replacement of an intracorporeal left ventricular assist deviceAnnals of Thoracic Surgery.  64:839-841. 1997
1997 The impact of a defensive response set on the relationship between MMPI and cognitive tests among heart transplant candidatesAssessment.  4:365-375. 1997
1996 Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database Group.Circulation.  94:2883-2889. 1996
1996 Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional studyJournal of Heart and Lung Transplantation.  15:329-341. 1996
1996 A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionNew England Journal of Medicine.  334:296-300. 1996
1996 Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation results of a prospective, randomized multicenter trialJournal of the American College of Cardiology.  27:1707-1712. 1996
1996 Infections during extended circulatory support: University of Alabama at Birmingham experience 1989 to 1994Annals of Thoracic Surgery.  61:366-371. 1996
1996 Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994: A multi-institutional studyCirculation.  94:2883-2889. 1996
1996 Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registryAmerican Journal of Cardiology.  78:532-535. 1996
1995 Selection and treatment of candidates for heart transplantation: A statement for health professionals from the committee on heart failure and cardiac transplantation of the council on clinical cardiology, American Heart AssociationCirculation.  92:3593-3612. 1995
1995 Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failureAmerican Journal of Cardiology.  75. 1995
1995 Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection 1995
1995 Safety and efficacy of epoprostenol in patients with severe congestive heart failureAmerican Journal of Cardiology.  75:34A-43A. 1995
1995 Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.American Journal of Cardiology.  75:34A-43A. 1995
1995 Cardiac transplant coronary artery disease: A multivariable analysis of pretransplantation risk factors for disease development and morbid eventsJournal of Thoracic and Cardiovascular Surgery.  109:1081-1089. 1995
1995 Circulatory support for myocardial infarction with ventricular arrhythmiasAnnals of Thoracic Surgery.  59:1230-1231. 1995
1995 Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipientsJournal of the American College of Cardiology.  26:120-128. 1995
1995 Left atrial or ventricular cannulation beyond 30 days for a Thoratec ventricular assist deviceASAIO Journal.  41. 1995
1995 Lisinopril Versus Placebo in the Treatment of Heart Failure: The Lisinopril Heart Failure Study GroupJournal of Clinical Pharmacology.  35:673-680. 1995
1995 Predictors of quality of life in patients with advanced heart failure awaiting transplantationJournal of Heart and Lung Transplantation.  14:2-10. 1995
1995 Predictors of quality of life in patients with advanced heart failure awaiting transplantation.Journal of Heart and Lung Transplantation.  14:2-10. 1995
1995 Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysisJournal of Heart and Lung Transplantation.  14:409-418. 1995
1995 Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group.Journal of Heart and Lung Transplantation.  14:409-418. 1995
1995 Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipientsJournal of Heart and Lung Transplantation.  14:856-864. 1995
1994 Treatment of recurrent heart rejection with mycophenolate mofetil (RS- 61443): Initial clinical experienceJournal of Heart and Lung Transplantation.  13:444-450. 1994
1994 Cytomegalovirus after heart transplantation. Risk factors for infection and death: A multiinstitutional studyJournal of Heart and Lung Transplantation.  13:394-404. 1994
1994 Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.Journal of Heart and Lung Transplantation.  13:394-404. 1994
1994 Infection after heart transplantation: A multiinstitutional studyJournal of Heart and Lung Transplantation.  13:381-393. 1994
1994 Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group.Journal of Heart and Lung Transplantation.  13:381-392. 1994
1994 Influence of HLA mismatch on rejection after heart transplantation: A multiinstitutional studyJournal of Heart and Lung Transplantation.  13:583-596. 1994
1994 Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group.Journal of Heart and Lung Transplantation.  13:583-595. 1994
1994 Influence of longer term left ventricular assist device support on valvular regurgitationASAIO Journal.  40. 1994
1994 Invited letter concerning: Acute interstitial nephritis in a cardiac transplant recipient receiving ciprofloxacinJournal of Thoracic and Cardiovascular Surgery.  107:1364-1365. 1994
1994 Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: A multivariable, multiinstitutional reportJournal of Heart and Lung Transplantation.  13:353-365. 1994
1994 Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group.Journal of Heart and Lung Transplantation.  13:353-364. 1994
1993 Influence of left ventricular assist on valvular regurgitation.Circulation.  88:II309-II318. 1993
1993 Long-term function of cryopreserved aortic homografts: A ten-year studyJournal of Thoracic and Cardiovascular Surgery.  106:154-166. 1993
1993 Pretransplantation risk factors for acute rejection after heart transplantation: A multiinstitutional studyJournal of Heart and Lung Transplantation.  12:355-366. 1993
1993 Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group.Journal of Heart and Lung Transplantation.  12:355-366. 1993
1993 Pretransplantation risk factors for death after heart transplantation: A multiinstitutional studyJournal of Heart and Lung Transplantation.  12:549-562. 1993
1993 Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group.Journal of Heart and Lung Transplantation.  12:549-562. 1993
1993 Task force 4: Function of the heart trnsplant recipientJournal of the American College of Cardiology.  22:31-41. 1993
1993 Total lymphoid irradiation: is there a role in pediatric heart transplantation?Journal of Heart and Lung Transplantation.  12:S293-S300. 1993
1993 Use of expanded polytetrafluoroethylene pericardial substitute with ventricular assist devicesAnnals of Thoracic Surgery.  55:181-183. 1993
1992 Methotrexate pulse therapy in the treatment of recurrent acute heart rejectionJournal of Heart and Lung Transplantation.  11:1116-1124. 1992
1992 Rejection after cardiac transplantation. A time-related risk factor analysis.Circulation.  86:II236-II241. 1992
1992 Application of Echocardiographic Color Flow Doppler Mitral Regurgitation to the Diagnosis of Acute Cardiac Transplant Rejection 1992
1992 Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II studyAmerican Journal of Cardiology.  69:1-9. 1992
1992 Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of a multicenter trialCirculation.  85:942-949. 1992
1992 Cardiac transplantation: Recipient selection, donor procurement, and medical follow-up: A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart AssociationCirculation.  86:1061-1079. 1992
1992 Coronary angioplasty in cardiac transplant patients: Results of a multicenter studyCirculation.  86:458-462. 1992
1992 Cyclosporine blood monitoring after heart transplantation: A prospective comparison of monoclonal and polyclonal radioimmunoassaysJournal of Heart and Lung Transplantation.  11:522-529. 1992
1992 Cyclosporine blood monitoring after heart transplantation: a prospective comparison of monoclonal and polyclonal radioimmunoassays.Journal of Heart and Lung Transplantation.  11:522-529. 1992
1992 Cytomegalovirus Colitis Presenting as Hematochezia and Requiring ResectionJAMA Surgery.  127:102-104. 1992
1992 Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heartJournal of Heart and Lung Transplantation.  11:584-586. 1992
1992 Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart.Journal of Heart and Lung Transplantation.  11:584-586. 1992
1992 Total lymphoid irradiation in the treatment of early or recurrent heart rejectionJournal of Heart and Lung Transplantation.  11:902-912. 1992
1991 Long-term effect of thrombolytic therapy on left ventricular ejection fraction after acute myocardial infarctionAmerican Journal of Cardiology.  67:1354-1359. 1991
1991 Diltiazem-cyclosporine interaction in cardiac transplant recipients: impact on cyclosporine dose and medication costs.American Journal of Medicine.  90:402-404. 1991
1991 Analysis and predictors of pulmonary vascular resistance after cardiac transplantationJournal of Thoracic and Cardiovascular Surgery.  101:432-445. 1991
1991 Case report: Circulatory support for seventy days with resolution of acute heart failure [2]Journal of Thoracic and Cardiovascular Surgery.  102:932-934. 1991
1991 Diltiazem-cyclosporine interaction in cardiac transplant recipients: Impact on cyclosporine dose and medication costsAmerican Journal of Medicine.  90:402-404. 1991
1990 Gastrointestinal complications after cardiac transplantation. Potential benefit of early diagnoses and prompt surgical interventionAnnals of Surgery.  211:538-542. 1990
1990 Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3Journal of Thoracic and Cardiovascular Surgery.  99:716-724. 1990
1990 Transesophageal Echocardiographic Evaluation of Mechanical Biventricular Assist Device 1990
1989 Arrhythmias after orthotopic cardiac transplantation. Prevalence and determinants during initial hospitalization and late follow-up.Circulation.  80:III140-III146. 1989
1989 Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot studyAmerican Journal of Cardiology.  63:503-512. 1989
1989 Arrhythmias after orthotopic cardiac transplantation. Prevalence and determinants during initial hospitalization and late follow-upCirculation.  80:140-146. 1989
1989 Coronary artery to right ventricle fistula in heart transplant recipients: A complication of endomyocardial biopsyJournal of the American College of Cardiology.  14:258-261. 1989
1988 Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine.American Journal of Medicine.  85:452-453. 1988
1988 Pulmonary vascular resistance and the risk of heart transplantationJournal of Heart and Lung Transplantation.  7:331-336. 1988
1988 Synergistic nephrotoxicity due to ciprofloxacin and cyclosporineAmerican Journal of Medicine.  85:452-453. 1988
1986 Have the results of mitral valve replacement improved?Journal of Thoracic and Cardiovascular Surgery.  92:186-197. 1986

Chapter

Year Title Altmetric
2008 Role of left ventricular assist devices in acute heart failure syndrome and the future of the replacement heart.  737-747. 2008

Principal Investigator On

  • Mechanisms of B Cell Responses in Autoimmune Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituxibab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)  awarded by Duke University
  • Private Grant  awarded by MEDTRONIC, INC.
  • Private Grant  awarded by MEDTRONIC, INC.
  • Private Grant  awarded by ZEALAND PHARMA
  • Private Grant  awarded by HESPERION USA, INC.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by MEDTRONIC, INC.
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC.
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC.
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by MEDTRONIC, INC.
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GENO LLC
  • Private Grant  awarded by GENO LLC
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MEDTRONIC, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by INO THERAPEUTICS, INC.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC
  • Private Grant  awarded by BELLEROPHON PULSE TECHNOLOGIES LLC
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC
  • Investigator On

  • A Randomized, Controlled Phase 1 Study of External Counterplusation as a Treatment for Acute Ischemic Stoke - (CUFFS)  awarded by University of California, San Diego
  • Genomic Classification of the Heart Transplant Endomyocardial Biopsy  awarded by American Heart Association (Southeast Affiliate)
  • Genomic Classification of the Heart Transplant Endomyocardial Biopsy  awarded by University of California, Los Angeles
  • Long Term Outcome Follow-Up of the RAD001 B253 Study, Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients  awarded by Cedars - Sinai Medical Center
  • Private Grant  awarded by LILLY-ICOS, LLC
  • Private Grant  awarded by CARDIOMEMS, INC.
  • Private Grant  awarded by VENTRACOR, INC.
  • Private Grant  awarded by VENTRACOR, INC.
  • Private Grant  awarded by CARDIOMEMS, INC.
  • Private Grant  awarded by SUNSHINE HEART, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by SYNVISTA THERAPEUTICS, INC.
  • Private Grant  awarded by SYNVISTA THERAPEUTICS, INC.
  • Private Grant  awarded by TERUMO HEART, INC
  • Private Grant  awarded by ACORN CARDIOVASCULAR, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by PARACOR MEDICAL, INC.
  • Private Grant  awarded by PARACOR MEDICAL, INC.
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by CARDIOXYL PHARMACEUTICALS, INC.
  • Private Grant  awarded by EVAHEART, INC.
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by HEARTWARE, INC.
  • Private Grant  awarded by CARDIOVASCULAR CLINICAL SCIENCE FOUNDATION
  • Private Grant  awarded by BIOCONTROL MEDICAL
  • Private Grant  awarded by SUNSHINE HEART, INC.
  • Private Grant  awarded by St. Jude Medical
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC.
  • Private Grant  awarded by GAMBRO HEALTHCARE
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd.
  • Private Grant  awarded by HEARTWARE, INC.
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC.
  • Private Grant  awarded by EIGER BIOPHARMACEUTICALS, INC.
  • Private Grant  awarded by EIGER BIOPHARMACEUTICALS, INC.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by LIVANOVA USA, INC.
  • Private Grant  awarded by COMPLEXA, INC.
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC
  • Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support  awarded by Northwestern University
  • Treatment of Preserved Cardiac Function Heart Failure with an Aldosterine Antagonist (TOPCAT)  awarded by NEW ENGLAND RESEARCH INSTITUTE
  • Teaching Activities

  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2009)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011)
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Louisiana State University Health Sciences Center - New Orleans 1979
  • Full Name

  • Robert Bourge